YesalisC.Incidence of anabolic steroid use: a discussion of methodological issues. In: YesalisC, ed. Anabolic Steroids in Sport and Exercise.Champaign, Ill: Human Kinetics Publishers, 1993: 49–69.
2.
BuckleyWYesalisCFriedlKAndersonWStreitAWrightI.Estimated prevalence of anabolic steroid use among male high school seniors. JAMA1988; 260: 3441–5.
3.
PerryHMWrightDLittlepageBNC.Dying to be big: a review of anabolic steroid use. Br J Sports Med.1992; 26: 259–61.
4.
GlazerG.Atherogenic effects of anabolic steroids on serum lipid levels. Arch Intern Med.1991; 151: 1925–33.
5.
CohenJCFaberWMBenadeAJSNoakesTD.Altered serum lipoprotein profiles in male and female power lifters ingesting anabolic steroids. Phys Sports Med.1986; 14: 131–6.
6.
CostillDLPearsonDRFinkWJ.Anabolic steroid use among athletes: changes in HDL-C levels. Phys Sports Med.1984; 12: 113–17.
7.
ThompsonPDCullinaneEMSadySPChenevertCSaritelliALSadyMAContrasting effects of testosterone and stanazolol on serum lipoprotein levels. JAMA1989; 261: 1165–8.
8.
LendersJWDemackerPNVosJAJansenPLHoitsmaAJVan't LaarADeleterious effects of anabolic steroids on serum lipoprotein, blood pressure, and liver function in amateur body builders. Int J Sports Med.1988; 9: 249–52.
9.
Applebaum-BowdenDHaffnerSMHazzardWR.The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein cholesterol. Metabolism1987; 36: 949–52.
10.
AlbersJJTaggartHMApplebaum-BowdenDHaffnerSChesnutCHazzardWReduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the LP(a) lipoprotein with the anabolic steroid stanazolol. Biochim Biophys Acta1984; 795: 293–6.
